Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 1422 results for social care

  1. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

    In development [GID-TA10571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  2. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  3. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

    Clinical guideline
    Published
    29 November 2005
    View recommendations

    Sections for CG31

  5. Help implement NICE guidance

    Join our panel to give your expert advice on tools and resources developed to support NICE guidance.

  6. Bismuth subcitrate potassium–metronidazole–tetracycline hydrochloride with omeprazole for treating Helicobacter pylori and preventing peptic ulcer relapse TS ID 11900

      Status ...

    Health technology evaluations
    Topic selection

  7. NICE guidance

    the best available evidence to develop guidance to improve health and social care. Our guidance takes many forms. From this page, you...

  8. Medical technologies evaluation programme process guide (PMG34)

    Medical technologies evaluation programme process guide

  9. Third molars (impacted) - prophylactic removal [ID898]

    In development [GID-TAG525] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

    Awaiting development [GID-TA10909] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development [GID-TA10638] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Cladribine for treating relapsing multiple sclerosis [ID6263]

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  13. What are the most appropriate ways to collect and manage data about domestic violence and abuse across the health, social care and criminal justice sectors? Is there value in collecting anonymised aggregate data, or is there a more useful method of data capture?

    and manage data about domestic violence and abuse across the health, social care and criminal justice sectors? Is there value in...

    Research recommendation
    Published
    9 June 2015

  14. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

    Quality standard
    Published
    11 May 2018
    View quality statements

    Sections for QS167

  15. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable ID 6272

      Status ...

    Health technology evaluations
    Topic selection